SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is being discussed amid a broad crypto pullback, with traders citing concerns about a reported major Binance security incident alongside persistent technical weakness. Bearish voices warn of more downside, while others view the dip as a buying opportunity and say they are accumulating or staking SOL.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs pending decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders weighing the amended application and upper-limb data against the earlier negative AdCom and statistical concerns. Bulls read recent launch hiring and a more flexible rare-disease regulatory climate as encouraging signs, while skeptics stress that neither hiring nor community advocacy guarantees approval.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries and sharply higher overseas sales are drawing attention, with traders debating whether the volume growth can translate into better margins and support its Q4 targets. The operational news is met with caution as many point to the stocks prolonged decline, China EV competition and profitability concerns.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons stronger-than-expected Q3 results, led by a surge in refining earnings, and its planned shareholder returns have drawn attention as the stock reached a 52-week high. Traders are debating whether the breakout can continue or the shares look extended after the run-up.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

Discussion centers on the planned VIP dinner for top TRUMP token holders, which traders view as a possible source of renewed interest; others see the event as another promotion for a highly speculative meme coin. Many posters focus on the tokens steep losses and describe it as a pump-and-dump, while some remain bullish on short-term rebounds.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to fresh 52-week highs is drawing attention ahead of its expected Q3 report, with traders focused on whether BRIUMVIs sales momentum and guidance will support the rally. Buyout and short-squeeze theories are adding to the bullish chatter, but neither is confirmed, and some traders warn that expectations may already be elevated.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gileads stronger-than-expected quarterly results, raised product-sales outlook and continued HIV-franchise growth are driving attention as shares reach fresh highs. Traders are broadly positive on the results, while some interpret put-heavy options activity as possible profit-taking or a hedge after the run-up.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, E-Vapor Products and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The E-Vapor Products segment contracts with third-party importers to supply all of its products and sells its e-vapor products to customers in the United States. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altrias third-quarter report beat expectations, lifted its full-year outlook and expanded its buyback, drawing attention as shares approached record highs. Traders welcomed the earnings and shareholder-return news, while some remained cautious about declining cigarette volumes and the sustainability of the rally.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention amid a sharp pullback alongside other AI and optical-networking stocks, with traders pointing to broader AI-sector selling and concerns about spending, valuation, and further share dilution rather than a confirmed company-specific catalyst. The move has split the community between dip buyers betting on data-center demand and bearish traders worried about continued downside ahead of earnings.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is drawing attention as Middle East conflict and threats to shipping through the Strait of Hormuz keep oil-supply risks in focus, supporting energy stocks and sector-rotation interest. Traders are broadly bullish on energys strength, while some warn the rally is extended and could reverse if diplomacy eases the geopolitical risk premium.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened?

Equity

The company said that the new data indicate that GRI-0621 may support the regeneration of lung tissue.

GRI Bio Drug Shows Promising Lung Function Recovery In Patients With Thickened Lungs

GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lung disease with no known cause.read more...

Barclays lifts Kojamo, I-RES ratings; cuts Grainger on low yield

This account has been verified as an official GRI representative.

Verified Account

GRI Bio

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

GRI Bio Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury.</li><li>Prior Phase 2a results had already shown favorable safety and tolerability, as well as reduced disease progression.</li><li>Stocktwits users speculated that short selling could be the reason behind the stock’s decline.</li></ul>GRI Bio, Inc. (GRI), on Wednesday, announced encouraging new results from its Phase 2a study of GRI-0621 in patients with Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease.The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar repair compared with placebo.<h2 class="st-heading-2">Treatment May Support Lung Tissue Regeneration</h2>Crucially, the new data indicate that GRI-0621 may support the regeneration of lung tissue, including the repair of the alveolar basement membrane and the&nbsp;transition of AT2 (Alveolar Type) epithelial cells to AT1, which are key steps in restoring lung function.Prior Phase 2a results had already shown favorable safety and tolerability, reduced disease progression, and improvements in exploratory endpoints, such as forced vital capacity, with twice as many treated patients maintaining lung function compared with standard care.“The data from the Phase 2a study exceed our expectations. The totality of data generated in this Phase 2a study suggests that GRI-0621 may represent a fundamentally different approach, with the potential to alter the trajectory of disease by promoting repair of damaged lung tissue,” said Marc Hertz, chief executive officer of GRI Bio.<h2 class="st-heading-2">Short Selling Speculation</h2>However, despite the seemingly positive development, <a href="https://stocktwits.com/symbol/GRI">GRI shares</a> fell 20%. But users remained bullish, despite what many speculated as short selling.<stembedurl>https://stocktwits.com/Tradebub/message/643136568</stembedurl><stembedurl>https://stocktwits.com/Kookoovia/message/643141732</stembedurl>Despite the sharp intra-day decline, retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier. GRI was also among the top trending tickers on the platform.<h2 class="st-heading-2">Reverse Split</h2>Last week, GRI Bio announced a 1-for-28 reverse stock split to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.The action became effective after-market hours on January 23, 2026, while trading on an ex-reverse split basis began on Monday. The split reduced outstanding shares from about 15 million to 536,000.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sbux-stock-climbs-7-premarket-after-q1-results/cmyg421R40I">SBUX Stock Jumps 7% Today – US Transactions Grow For The First Time In Two Years</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

SPDR Dow Jones Global Real Estate ETF

SPDR Dow Jones International Real Estate ETF

SPDR Portfolio Europe ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$GRI Marc and team have not produced any thing since this scam started.. pump and dump and mamangement draws a great living while investors never get the real reward of scaling up. Reverse splits give this a good eye till you dig into the weeds and all you see is thorns and your wallet just keeps missing $$$ 
Really who has made lots of money on this stock besides the pump and dump game?

Robert Moss

$GRI fucking piece of crap !!! i see asian stocks going up 500% almost everyday, but US stocks are dead

$GRI even worst of the worst stock have gone up 1000% in last 3-4 months. JAGX, DFNS, VEEE, XHLD, VCIG. i mean why the fuck has this stock stayed dead

$GRI all micro cap stocks are in the toilet. how could this stay up? volume is so low, people are scared

$GRI lol and down it goes… so nothing from that call at midnight uh? This going down to 1.38 ATL this week

$GRI Marc and team have scam the buyers for yrs now… so many presentations and no results; lots of salary for what???

Feed

News

Sentiment

Fundamentals

Info

GRI GRI Bio Inc

Fundamentals

Latest GRI News